[{"indications": "Indications\u00a0prophylaxis of venous thromboembolism in medical patients immobilised\r\nbecause of acute illness, and patients undergoing major orthopaedic\r\nsurgery of the hip or leg, or abdominal surgery; treatment of deep-vein\r\nthrombosis, superficial-vein thrombosis, and pulmonary embolism; treatment\r\nof unstable angina or non-ST-segment elevation myocardial infarction;\r\ntreatment of ST-segment elevation myocardial infarction", "name": "FONDAPARINUX SODIUM", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.8 Anticoagulants and protamine", "2.8.1 Parenteral anticoagulants", "Fondaparinux", "FONDAPARINUX SODIUM"], "cautions": "Cautions\u00a0bleeding disorders, active gastro-intestinal ulcer disease; recent intracranial haemorrhage; brain, spinal, or ophthalmic surgery; spinal or epidural anaesthesia (risk of spinal haematoma\u2014avoid if using treatment doses); risk of catheter thrombus during percutaneous coronary intervention; low body-weight; elderly\r\npatients; concomitant use of drugs that\r\nincrease risk of bleeding", "side-effects": "Side-effects\u00a0bleeding, purpura, anaemia; less commonly gastro-intestinal disturbances, oedema, hepatic impairment, chest\r\npain, dyspnoea, thrombocytopenia, thrombocythaemia, rash, pruritus; rarely hypotension, flushing, cough, vertigo, dizziness,\r\nanxiety, drowsiness, confusion, headache, hypokalaemia, hyperbilirubinaemia,\r\ninjection-site reactions; also reported atrial fibrillation, tachycardia,\r\nand pyrexia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/112796.htm", "doses": ["Prophylaxis of venous thromboembolism after surgery, by subcutaneous injection, 2.5\u00a0mg 6 hours after surgery then\r\n2.5\u00a0mg once daily; child under 17 years\r\nnot recommended", "Prophylaxis of venous thromboembolism in medical patients, by subcutaneous injection, 2.5\u00a0mg once daily; child under 17 years not recommended", "Treatment of superficial-vein thrombosis, by subcutaneous\r\ninjection, adult body-weight\r\nover 50\u00a0kg, 2.5\u00a0mg once daily for at least 30 days (max. 45 days if\r\nhigh risk of thromboembolic complications); treatment should be stopped\r\n24 hours before surgery and restarted at least 6 hours post operatively; child under 17 years not recommended", "Unstable angina and non-ST-segment elevation myocardial\r\ninfarction, by subcutaneous injection, 2.5\u00a0mg once\r\ndaily for up to 8 days (or until hospital discharge if sooner); treatment\r\nshould be stopped 24 hours before coronary artery bypass graft surgery\r\n(where possible) and restarted 48 hours post operatively; child under 17 years not recommended", "ST-segment elevation myocardial infarction, initially by intravenous injection or infusion, 2.5\u00a0mg\r\nfor first day, thereafter by subcutaneous injection 2.5\u00a0mg once daily for up to 8 days (or until hospital discharge\r\nif sooner); treatment should be stopped 24 hours before coronary artery\r\nbypass graft surgery (where possible) and restarted 48 hours post\r\noperatively; child under 17 years not\r\nrecommended", "Treatment of deep-vein thrombosis and of pulmonary embolism, by subcutaneous injection, adult body-weight under 50\u00a0kg, 5\u00a0mg every 24 hours; body-weight 50\u2013100\u00a0kg,\r\n7.5\u00a0mg every 24 hours; body-weight over 100\u00a0kg, 10\u00a0mg every 24 hours; child under 17 years not recommended", "Note An oral anticoagulant (usually warfarin, section 2.8.2) is started at the same time\r\nas fondaparinux (fondaparinux should be continued for at least 5 days\r\nand until INR \u22652 for at least 24 hours)"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless potential benefit\r\noutweighs possible risk\u2014no information available"}]